Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

42.58 +0.39 (+0.92%)
Streaming Delayed Price Updated: 2:20 PM EDT, Jun 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,517,108
Open 42.11
Bid (Size) 42.58 (8)
Ask (Size) 42.59 (4)
Prev. Close 42.19
Today's Range 41.71 - 43.04
52wk Range 39.63 - 65.38
Shares Outstanding 2,222,113,553
Dividend Yield 5.35%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What the Options Market Tells Us About Bristol-Myers Squibb
Via Benzinga
FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation
The FDA granted accelerated approval to Bristol Myers Squibb's Krazati (adagrasib) with cetuximab for adult patients with KRASG12C-mutated advanced or metastatic colorectal cancer. 
Via Benzinga
Exposures Product Safety

Performance

YTD
-19.29%
-19.29%
1 Month
+5.16%
+5.16%
3 Month
-18.97%
-18.97%
6 Month
-17.24%
-17.24%
1 Year
-34.28%
-34.28%

More News

Read More
7 Dividend Stocks to Buy Now: June 2024
Via InvestorPlace
AbbVie Inc. Dividend Stock Analysis - Saturday, June 22
Via Talk Markets
S&P 500 Earnings Dashboard 24Q1 - Saturday, June 22
Via Talk Markets
Topics Stocks
Exposures US Equities
Bristol-Myers Squibb Stock Price Forecast: Is The Downtrend Finally Over?
Via Talk Markets
This Is What Whales Are Betting On Bristol-Myers Squibb
Via Benzinga
3 No-Brainer Stocks to Buy for Under $100 Right Now
Via The Motley Fool
3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold
Via The Motley Fool
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
From Bristol Myers Squibb
Via Business Wire
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Via Benzinga
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab
From Bristol Myers Squibb
Via Business Wire
German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
Via Benzinga
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
From Bristol Myers Squibb
Via Business Wire
3 Warren Buffett Stocks to Buy Now: June 2024
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors
From Bristol Myers Squibb
Via Business Wire
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb
Via The Motley Fool
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
Via InvestorPlace
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
Via FinancialNewsMedia
3 High-Yield S&P 500 Dividend Stocks Down More Than 25% to Buy Now and Hold for at Least a Decade
Via The Motley Fool
Topics Stocks
Exposures US Equities
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
From FN Media Group LLC
Via GlobeNewswire
3 High-Yield Dividend Stocks for Income Now and Growth Later
Via MarketBeat
Topics Economy
Exposures Interest Rates
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
From Bristol Myers Squibb
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.